Background
Landmark prospective randomized trial (NCI) evaluating limb-sparing surgery + adjuvant radiation therapy vs. amputation for high-grade soft tissue sarcomas of the extremities. 43 adult patients with high-grade extremity STS, 1975–1981. Randomization 2:1 (27 limb-sparing, 16 amputation). Both arms received adjuvant chemotherapy (doxorubicin, cyclophosphamide, high-dose methotrexate).
Interventions and follow up
Arm A: Limb-sparing resection + adjuvant RT (50 Gy to anatomic area at risk + 60–70 Gy to tumor bed) + chemotherapy
Arm B: Amputation at/above proximal joint + chemotherapy
Primary endpoint: Local recurrence, disease-free survival, overall survival
mFollow up: 5 year
Arm B: Amputation at/above proximal joint + chemotherapy
Primary endpoint: Local recurrence, disease-free survival, overall survival
mFollow up: 5 year
Results
Local Recurrence: Limb-sparing 4/27 (15%) vs. amputation 0/16 (0%), P=.06
5-Year DFS: 71% vs. 78%, P=.75 — no significant difference
5-Year OS: 83% vs. 88%, P=.99 — no significant difference
Margin status: Positive margins associated with higher LR (P<.0001) even with RT
5-Year DFS: 71% vs. 78%, P=.75 — no significant difference
5-Year OS: 83% vs. 88%, P=.99 — no significant difference
Margin status: Positive margins associated with higher LR (P<.0001) even with RT
Adverse events
Main adverse events: Limb-sparing arm: radiation dermatitis, wound complications, edema, functional impairment; significantly better limb function and quality of life vs. amputation. Amputation: phantom limb pain, prosthetic limitations. Chemotherapy toxicity in both arms (myelosuppression, doxorubicin cardiomyopathy risk).
Conclusions
Limb-sparing surgery plus adjuvant RT achieves equivalent overall survival and disease-free survival to amputation in high-grade extremity STS, establishing limb preservation as the standard of care. The small increase in local recurrence with limb-sparing is offset by preservation of function with no OS cost.
Key Limitations
Key Limitations: Small sample (n=43); limited statistical power for subset analyses; mandatory adjuvant chemotherapy in both arms confounds RT contribution; 2:1 randomization ratio unusual; high-dose methotrexate regimen not standard today; margin quality data limited.
Clinical Context
This NCI trial fundamentally changed sarcoma surgery. Before 1975, amputation was standard; this trial established that RT enables limb salvage with equivalent survival. Combined with the Yang EBRT trial and Pisters brachytherapy trial, it forms the foundational evidence for limb-sparing surgery + RT in extremity STS (now >90% of cases managed with limb preservation).
References